13-04-2025 | NSCLC | REVIEW ARTICLE

Is SBRT the optimal first-line treatment for operable early-stage NSCLC in elderly patients?

Authors: Ana Maria Soto-Cambres, Núria Farré

Published in: Clinical and Translational Oncology

Abstract

The introduction of screening programs and the increase in life expectancy in developed countries have significantly raised the incidence of early-stage non-small cell lung cancer (ES-NSCLC). Surgery remains the standard of care for ES-NSCLC; however, stereotactic body radiotherapy (SBRT) has become the treatment of choice for patients with inoperable ES-NSCLC. Despite its growing use, there is a lack of robust data from randomized phase III trials comparing SBRT to surgery, mostly due to challenges in recruitment. This gap is particularly pronounced in the elderly, who are often excluded from clinical studies. With the rising incidence of ES-NSCLC and an aging population, non-invasive therapies like SBRT may offer significant advantages by minimizing treatment-related morbidity while effectively controlling the disease. This review critically evaluates the current literature on managing ES-NSCLC in elderly patients and assesses the potential benefits and limitations of SBRT as a standard of care in this complex population.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed

Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US. JAMA Oncol. 2021;7(12):1824–32.CrossRefPubMed

Global Cancer Observatory: Cancer Tomorrow. Lyon, France: International Agency for Research on Cancer; 2018. Last access: October 20th, 2019. Available in https://gco.iarc.who.int

Nguyen NP, Godinez J, Shen W, Vinh-Hung V, Gorobets H, Thariat J, Ampil F, Vock J, Karlsson U, Chi A, International Geriatric Radiotherapy Group. Is surgery indicated for elderly patients with early stage nonsmall cell lung cancer, in the era of stereotactic body radiotherapy? Medicine (Baltimore). 2016;95(43):e5212. https://doi.org/10.1097/MD.0000000000005212. PMID: 27787380; PMCID: PMC5089109

Maebayashi T, Ishibashi N, Aizawa T, Sakaguchi M, Saito T, Kawamori J, Tanaka Y. Significance of stereotactic body radiotherapy in older patients with early stage non-small cell lung cancer. J Geriatr Oncol. 2018;9(6):594–9. https://doi.org/10.1016/j.jgo.2018.03.005. Epub 2018 Mar 21. PMID: 29573969.CrossRefPubMed

Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e278S-e313S.CrossRefPubMed

Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C, Peters S. Early-stage and locally advanced (non-metastatic) non-small-cell-lung-cancer: ESMO practice guidelines. Ann Oncol. 2017;28(suppl 4):iv1–iv21

NCCN guidelines. Non-Small-Cell-Lung Cancer. v11.2024

Naunheim KS, Kesler KA, D’Orazio SA, Fiore AC, Judd DR. Lung cancer surgery in the octogenarian. Eur J Cardiothorac Surg. 1994;8(9):453–6. https://doi.org/10.1016/1010-7940(94)90013-2.CrossRefPubMed

10.

Deslauriers J, Ginsberg RJ, Piantadosi S, Fournier B. Prospective assessment of 30-day operative morbidity for surgical resections in lung cancer. Chest. 1994;106(6 Suppl):329S-330S.CrossRefPubMed

11.

Berry MF, Hanna J, Tong BC, Burfeind WR Jr, Harpole DH, D’Amico TA, Onaitis MW. Risk factors for morbidity after lobectomy for lung cancer in elderly patients. Ann Thorac Surg. 2009;88(4):1093–9.CrossRefPubMed

12.

Miura N, Kohno M, Ito K, Senba M, Kajiwara K, Hamaguchi N, Makino H, Kanematsu T, Okamoto T, Yokoyama H. Lung cancer surgery in patients aged 80 years or older: an analysis of risk factors, morbidity, and mortality. Gen Thorac Cardiovasc Surg. 2015;63(7):401–5.CrossRefPubMed

13.

Pei G, Zhou S, Han Y, Liu Z, Xu S. Risk factors for postoperative complications after lung resection for non-small cell lung cancer in elderly patients at a single institution in China. J Thorac Dis. 2014;6(9):1230–8.PubMedPubMedCentral

14.

Okada S, Shimomura M, Ishihara S, Ikebe S, Furuya T, Inoue M. Clinical significance of postoperative pulmonary complications in elderly patients with lung cancer. Interact Cardiovasc Thorac Surg. 2022;35(2)

15.

Onaitis MW, Furnary AP, Kosinski AS, Kim S, Boffa D, Tong BC, Cowper P, Jacobs JP, Wright CD, Putnam JB Jr, Fernandez FG. Prediction of long-term survival after lung cancer surgery for elderly patients in the society of thoracic surgeons general thoracic surgery database. Ann Thorac Surg. 2018;105(1):309–16.CrossRefPubMed

16.

Dominguez-Ventura A, Cassivi SD, Allen MS, Wigle DA, Nichols FC, Pairolero PC, Deschamps C. Lung cancer in octogenarians: factors affecting long-term survival following resection. Eur J Cardiothorac Surg. 2007;32(2):370–4.CrossRefPubMed

17.

Endoh H, Yamamoto R, Satoh Y, Kuwano H, Nishizawa N. Risk analysis of pulmonary resection for elderly patients with lung cancer. Surg Today. 2013;43(5):514–20.CrossRefPubMed

18.

Kaprin A, Pikin O, Ryabov A, Aleksandrov O, Larionov D, Garifullin A. Surgical intervention for lung cancer in patients aged 75 and above: potential associations with increased mortality rates-a single-center observational study. J Cardiothorac Surg. 2024;19(1):471.CrossRefPubMedPubMedCentral

19.

Thomas PA, Couderc AL, Boulate D, Greillier L, Charvet A, Brioude G, Trousse D, D’Journo XB, Barlesi F, Loundou A. Early-stage non-small cell lung cancer beyond life expectancy: still not too old for surgery? Lung Cancer. 2021;152:86–93.CrossRefPubMed

20.

Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, Groen HJ, McRae SE, Widder J, Feng L, van den Borne BE, Munsell MF, Hurkmans C, Berry DA, van Werkhoven E, Kresl JJ, Dingemans AM, Dawood O, Haasbeek CJ, Carpenter LS, De Jaeger K, Komaki R, Slotman BJ, Smit EF, Roth JA. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16(6):630–7. https://doi.org/10.1016/S1470-2045(15)70168-3. Epub 2015 May 13. Erratum in: Lancet Oncol. 2015;16(9):e427. https://doi.org/10.1016/S1470-2045(15)00238-7. PMID: 25981812; PMCID: PMC4489408

21.

Takeda A, Sanuki N, Eriguchi T, Kaneko T, Morita S, Handa H, Aoki Y, Oku Y, Kunieda E. Stereotactic ablative body radiation therapy for octogenarians with non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013;86(2):257–63. https://doi.org/10.1016/j.ijrobp.2013.01.006. (Epub 2013 Apr 6 PMID: 23570699).CrossRefPubMed

22.

Watanabe K, Katsui K, Sugiyama S, Yoshio K, Kuroda M, Hiraki T, Kiura K, Maeda Y, Toyooka S, Kanazawa S. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study. Radiat Oncol. 2021;16(1):39. https://doi.org/10.1186/s13014-021-01769-7.PMID:33622369;PMCID:PMC7903684.CrossRefPubMedPubMedCentral

23.

Bei Y, Murakami N, Nakayama Y, Okuma K, Kashihara T, Raturi VP, Okamoto H, Takahashi K, Inaba K, Igaki H, Itami J. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer in octogenarians and older: an alternative treatment. J Radiat Res. 2020;61(4):586–93. https://doi.org/10.1093/jrr/rraa027. (PMID: 32383730; PMCID: PMC7336556).CrossRefPubMedPubMedCentral

24.

Miyazaki T, Yamazaki T, Nakamura D, Sato S, Yamasaki N, Tsuchiya T, Matsumoto K, Kamohara R, Hatachi G, Nagayasu T. Surgery or stereotactic body radiotherapy for elderly stage I lung cancer? A propensity score matching analysis. Surg Today. 2017;47(12):1476–83. https://doi.org/10.1007/s00595-017-1536-4. (Epub 2017 Apr 26 PMID: 28447170).CrossRefPubMed

25.

Shu Z, Dong B, Shi L, Shen W, Hang Q, Wang J, Chen Y. Stereotactic body radiotherapy for elderly patients (≥ 75 years) with early-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 2020;146(5):1263–1271. https://doi.org/10.1007/s00432-020-03154-5. Epub 2020 Feb 24. Erratum in: J Cancer Res Clin Oncol. 2021;147(10):3139. https://doi.org/10.1007/s00432-020-03469-3. PMID: 32095885

26.

Cassidy RJ, Patel PR, Zhang X, Press RH, Switchenko JM, Pillai RN, Owonikoko TK, Ramalingam SS, Fernandez FG, Force SD, Curran WJ, Higgins KA. Stereotactic body radiotherapy for early-stage non-small-cell lung cancer in patients 80 years and older: a multi-center analysis. Clin Lung Cancer. 2017;18(5):551–558.e6. https://doi.org/10.1016/j.cllc.2017.03.006. Epub 2017 Mar 16. PMID: 28373068; PMCID: PMC5783539

27.

Giuliani M, Hope A, Guckenberger M, Mantel F, Peulen H, Sonke JJ, Belderbos J, Werner-Wasik M, Ye H, Grills IS. Stereotactic body radiation therapy in octo- and nonagenarians for the treatment of early-stage lung cancer. Int J Radiat Oncol Biol Phys. 2017;98(4):893–9. https://doi.org/10.1016/j.ijrobp.2017.01.019. (Epub 2017 Jan 9 PMID: 28258901).CrossRefPubMed

28.

Hayashi S, Tanaka H, Kajiura Y, Ohno Y, Hoshi H. Stereotactic body radiotherapy for very elderly patients (age, greater than or equal to 85 years) with stage I non-small cell lung cancer. Radiat Oncol. 2014;16(9):138. https://doi.org/10.1186/1748-717X-9-138. (PMID: 24935216; PMCID: PMC4073190).CrossRef

29.

Mancini BR, Park HS, Harder EM, Rutter CE, Corso CD, Decker RH, Husain ZA. Elderly patients undergoing SBRT for inoperable early-stage NSCLC achieve similar outcomes to younger patients. Lung Cancer. 2016;97:22–7. https://doi.org/10.1016/j.lungcan.2016.04.011. (Epub 2016 Apr 19 PMID: 27237023).CrossRefPubMed

30.

Sandhu AP, Lau SK, Rahn D, Nath SK, Kim D, Song WY, Gulaya S, Fuster MM, Bazhenova L, Mundt AJ. Stereotactic body radiation therapy in octogenarians with stage I lung cancer. Clin Lung Cancer. 2014;15(2):131–5. https://doi.org/10.1016/j.cllc.2013.08.007. (Epub 2013 Oct 21 PMID: 24157245).CrossRefPubMed

31.

Nakagawa T, Negoro Y, Matsuoka T, Okumura N, Dodo Y. Comparison of the outcomes of stereotactic body radiotherapy and surgery in elderly patients with cT1-2N0M0 non-small cell lung cancer. Respir Investig. 2014;52(4):221–6. https://doi.org/10.1016/j.resinv.2014.01.002. (Epub 2014 Feb 26 PMID: 24998368).CrossRefPubMed

32.

Nanda RH, Liu Y, Gillespie TW, Mikell JL, Ramalingam SS, Fernandez FG, Curran WJ, Lipscomb J, Higgins KA. Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: a national cancer data base analysis. Cancer. 2015;121(23):4222–30. https://doi.org/10.1002/cncr.29640. (Epub 2015 Sep 8 PMID: 26348268).CrossRefPubMed

33.

Palma D, Visser O, Lagerwaard FJ, Belderbos J, Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol. 2010;28(35):5153–9. https://doi.org/10.1200/JCO.2010.30.0731. (Epub 2010 Nov 1 PMID: 21041709).CrossRefPubMed

34.

Paix A, Noel G, Falcoz PE, Levy P. Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer. Radiother Oncol. 2018;128(3):534–40. https://doi.org/10.1016/j.radonc.2018.04.013. (Epub 2018 Apr 26 PMID: 29706462).CrossRefPubMed

35.

Igarashi A, Onishi H, Shioyama Y, Matsumoto Y, Takayama K, Matsuo Y, Yamashita H, Miyakawa A, Matsushita H, Aoki M, Nihei K, Kimura T, Koba R, Lee DW, Ito K. Cost-utility analysis of stereotactic body radiation therapy versus surgery for patients with stage I non-small cell lung cancer in Japan. Int J Radiat Oncol Biol Phys. 2024;28:S0360-3016(24)03174-2. https://doi.org/10.1016/j.ijrobp.2024.07.2328. Epub ahead of print. PMID: 39352324

36.

Verstegen NE, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease. Radiother Oncol. 2011;101(2):250–4. https://doi.org/10.1016/j.radonc.2011.09.017. (Epub 2011 Nov 5 PMID: 22056535).CrossRefPubMed

37.

Videtic GMM, Woody NM, Reddy CA, Stephans KL. Never too old: a single-institution experience of stereotactic body radiation therapy for patients 90 years and older with early stage lung cancer. Pract Radiat Oncol. 2017;7(6):e543–e549. https://doi.org/10.1016/j.prro.2017.06.011. Epub 2017 Jun 29. PMID: 28867545

38.

Kreinbrink P, Blumenfeld P, Tolekidis G, Sen N, Sher D, Marwaha G. Lung stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer in the very elderly (≥ 80years old): extremely safe and effective. J Geriatr Oncol. 2017;8(5):351–5. https://doi.org/10.1016/j.jgo.2017.07.002. (Epub 2017 Jul 21 PMID: 28739159).CrossRefPubMed

39.

Eguchi T, Bains S, Lee MC, Tan KS, Hristov B, Buitrago DH, Bains MS, Downey RJ, Huang J, Isbell JM, Park BJ, Rusch VW, Jones DR, Adusumilli PS. Impact of increasing age on cause-specific mortality and morbidity in patients with stage I non-small-cell lung cancer: a competing risks analysis. J Clin Oncol. 2017;35(3):281–90. https://doi.org/10.1200/JCO.2016.69.0834. Epub 2016 Oct 31. PMID: 28095268; PMCID: PMC5456376

40.

van der Voort van Zyp NC, Prévost JB, van der Holt B, Braat C, van Klaveren RJ, Pattynama PM, Levendag PC, Nuyttens JJ. Quality of life after stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2010;77(1):31–7. https://doi.org/10.1016/j.ijrobp.2009.04.080. Epub 2009 Oct 26. PMID: 19864077

41.

Sun V, Kim JY, Williams AC, Raz DJ, Sampath S, Ferrell B. Quality of life and symptoms following stereotactic body radiotherapy in early-stage lung cancer patients. J Community Support Oncol. 2014;12(11):407–14. https://doi.org/10.12788/jcso.0087. (PMID: 25789332; PMCID: PMC4361026).CrossRefPubMedPubMedCentral

42.

Videtic GM, Reddy CA, Sorenson L. A prospective study of quality of life including fatigue and pulmonary function after stereotactic body radiotherapy for medically inoperable early-stage lung cancer. Support Care Cancer. 2013;21(1):211–8. https://doi.org/10.1007/s00520-012-1513-9. (Epub 2012 Jun 2 PMID: 22661073).CrossRefPubMed

43.

Schwartz RM, Alpert N, Rosenzweig K, Flores R, Taioli E. Changes in quality of life after surgery or radiotherapy in early-stage lung cancer. J Thorac Dis. 2019;11(1):154–61. https://doi.org/10.21037/jtd.2018.12.30. (PMID: 30863584; PMCID: PMC6384341).CrossRefPubMedPubMedCentral

44.

Leaman-Alcibar O, Cigarral C, Déniz C, Romero-Palomar I, Navarro-Martin A. Quality of life after stereotactic body radiation therapy versus video-assisted thoracic surgery in early stage non-small cell lung cancer. Is there enough data to make a recommendation? J Clin Transl Res. 2021;7(2):209–20. PMID: 34104823; PMCID: PMC8177842

45.

Iovoli AJ, Yu B, Ma SJ, Farrugia MK, Dexter EU, Yendamuri S, Bouchard EG, Singh AK. Quality of life after stereotactic body radiation therapy or surgery for early-stage NSCLC: a systematic review. JTO Clin Res Rep. 2022;3(11): 100417. https://doi.org/10.1016/j.jtocrr.2022.100417. (PMID: 36325154; PMCID: PMC9618999).CrossRefPubMedPubMedCentral

Title: Is SBRT the optimal first-line treatment for operable early-stage NSCLC in elderly patients?
Authors: Ana Maria Soto-Cambres
Núria Farré
Publication date: 13-04-2025
Publisher: Springer International Publishing
Keywords: NSCLC
NSCLC
Lung Cancer
Lung Cancer
Lung Cancer
Published in: Clinical and Translational Oncology
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-025-03914-0

Women’s health knowledge hub

Menopause
Clinical Collection

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Genetic Testing
On-demand Webinar

In this interactive webinar, experts Dr. Subbiah, Dr. Drilon, and Dr. Williams discuss best pathological practices within NSCLC and thyroid cancer, as well as how genomic testing can improve outcomes in clinical practice, using patient case studies as illustrations.

This content is intended only for US-based healthcare providers.

Supported by:

Illumina, Inc., and Eli Lilly and Company

Dr. Vivek Subbiah

Dr. Alexander Drilon

Dr. Michelle Williams

Developed by: Springer Healthcare

Watch now

Elevate your expertise in aplastic anemia (Link opens in a new window)

Aplastic Anemia
Independent Medical Education

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases.

Supported by:

Pfizer

Developed by: Springer Healthcare IME

Learn more

Navigating neuroimaging in Alzheimer disease care

Springer Medicine

Is SBRT the optimal first-line treatment for operable early-stage NSCLC in elderly patients?

Abstract

Women’s health knowledge hub

Incorporating comprehensive genomic profiling into the standard-of-care for NSCLC and thyroid cancer

Elevate your expertise in aplastic anemia (Link opens in a new window)

Navigating neuroimaging in Alzheimer disease care

Springer Medicine

Abstract

Please log in to get access to this content

Women’s health knowledge hub

Incorporating comprehensive genomic profiling into the standard-of-care for NSCLC and thyroid cancer

Elevate your expertise in aplastic anemia (Link opens in a new window)